• Japanese
  • Korean
  • Chinese
Cover Image

Cardiovascular Partnering Terms and Agreements

The ‘Cardiovascular Partnering Terms and Agreements’ report provides comprehensive understanding and unprecedented access to the cardiovascular partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cardiovascular partnering deals
  • Average deal terms for headline, upfront and royalty by stage of development
  • Cardiovascular partnering agreement structure
  • Cardiovascular partnering contract documents
  • Top cardiovascular deals by value
  • Most active cardiovascular dealmakers

The report provides a detailed understanding and analysis of how and why companies enter cardiovascular partnering deals. The majority of deals are discoveryor development stage whereby the licensee obtains a right or an option right to license the licensors cardiovascular technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 2,000 links to online copies of actual cardiovascular deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cardiovascular dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cardiovascular deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of cardiovascular deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of cardiovascular partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cardiovascular partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cardiovascular technologies and products.

Report scope

‘Cardiovascular Partnering Terms and Agreements’ is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide.

‘Cardiovascular Partnering Terms and Agreements’ includes:

  • Trends in cardiovascular dealmaking in the biopharma industry since 2009
  • Analysis of cardiovascular deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life cardiovascular deals
  • Access to over 2,000 cardiovascular deal records
  • The leading cardiovascular deals by value since 2009
  • Most active cardiovascular dealmakers since 2009
  • The leading cardiovascular partnering resources

In ‘Cardiovascular Partnering Terms and Agreements’, the available contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Cardiovascular Partnering Terms and Agreements’ report provides comprehensive access to available deals and contract documents for over 2,000 cardiovascular deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Cardiovascular Partnering Terms and Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of cardiovascular deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 2,000 actual cardiovascular contracts entered into by the world's biopharma companies
  • Detailed access to actual cardiovascular contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a cardiovascular agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cardiovascular dealmaking

  • 2.1. Introduction
  • 2.2. Cardiovascular partnering over the years
  • 2.3. Bigpharma cardiovascular dealmaking activity
  • 2.4. Bigpharma not active in cardiovascular
  • 2.5. Cardiovascular partnering by deal type
  • 2.6. Cardiovascular partnering by industry sector
  • 2.7. Cardiovascular partnering by stage of development
  • 2.8. Cardiovascular partnering by technology type
  • 2.9. Cardiovascular partnering by cardiovascular indication
  • 2.10. Average deal terms for cardiovascular
    • 2.10.1. Cardiovascular headline values
    • 2.10.2. Cardiovasular upfront payments
    • 2.10.3. Cardiovascular milestone payments
    • 2.10.4. Cardiovascular royalty rates

Chapter 3 - Leading cardiovascular deals

  • 3.1. Introduction
  • 3.2. Top cardiovascular deals by value
  • 3.3. Top cardiovascular deals involving bigpharma

Chapter 4 - Bigpharma cardiovascular deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma cardiovascular partnering company profiles
    • Abbott
    • Actavis
    • Actelion
    • Amgen
    • Aspen Pharmacare
    • Astellas
    • AstraZeneca
    • Bayer
    • Biogen Idec
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Daiichi Sankyo
    • Eisai
    • Eli Lilly
    • Forest Laboratories
    • Gilead Sciences
    • GlaxoSmithKline
    • Hospira
    • Johnson & Johnson
    • Lundbeck
    • Menarini
    • Merck & Co
    • Merck KGaA
    • Mitsubishi Tanabe
    • Novartis
    • Otsuka
    • Pfizer
    • Roche
    • Sanofi
    • Servier
    • Shire
    • Takeda
    • Teva
    • Valeant
    • Warner Chilcott
    • Watson

Chapter 5 - Cardiovascular partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
    • Asset purchase
    • Assignment
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Contract service
    • Co-promotion
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Joint venture
    • Licensing
    • Litigation
    • Loan
    • Manufacturing
    • Manufacturing - OEM
    • Marketing
    • Option
    • Promotion
    • Research
    • Royalty financing
    • Settlement
    • Spin out
    • Sub-license
    • Supply
    • Termination
    • Warranty
  • 5.3. By stage of development
    • Discovery
    • Preclinical
    • Phase I
    • Phase II
    • Phase III
    • Regulatory
    • Marketed
    • Formulation
  • 5.4. By technology type
    • Assays
    • Biodefense
    • Bioinformatics
    • Biological compounds
    • Biomarkers
    • Blood products
    • Cell therapy
    • Clinical testing
    • Diagnostic - companion
    • Devices
    • Diagnostics
    • Discovery tools
    • Drug delivery
    • Enabling technology
    • Equipment
    • Facilities
    • Gene therapy
    • Genomics
    • Imaging
    • Implant
    • Natural product
    • Oligonucleotide
    • Orphan drug
    • Packaging
    • Peptides
    • Personalised medicine
    • Processes
    • Proteomics
    • Recombinant DNA
    • Regenerative medicine
    • Research services
    • Research supplies
    • RNA therapeutics
    • Screening
    • Small molecules
    • Software tools
    • Stem cells

Chapter 6 - Cardiovascular dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
    • Cardiovascular
    • Abdominal aortic aneurysm
    • Angina
    • Arrhythmia
    • Atrial fibrillation
    • Long QT syndrome
    • Supraventricular Tachycardia
    • Atherosclerosis
    • Cardiogenic shock
    • Cardiomyopathy (heart muscle disease)
    • Chest pain
    • Congenital heart disease
    • Congestive heart failure
    • Coronary artery disease
    • Ductus arteriosus
    • Hypercholesterolemia
    • Hypertension
    • Intermittent claudication
    • Ischemic heart disease
    • Limb ischemia
    • Myocardial Infarction
    • Oedema (excess fluid)
    • Peripheral arterial disease
    • Thrombus (blood clot)
    • Restenosis
    • Varicose veins

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Directory of cardiovascular deals by company A-Z 2009-2014
  • Appendix 2 - Directory of cardiovascular deals by deal type 2009-2014
  • Appendix 3 - Directory of cardiovascular deals by stage of development 2009-2014
  • Appendix 4 - Directory of cardiovascular deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports

Table of Figures

  • Figure 1: Cardiovascular partnering since 2009
  • Figure 2: Bigpharma - top 50 - cardiovascular deals 2009 to 2012
  • Figure 3: Bigpharma cardiovascular deal frequency - 2009 to 2012
  • Figure 4: Inactive bigpharma in cardiovascular 2009-2014
  • Figure 5: Cardiovascular partnering by deal type since 2009
  • Figure 6: Cardiovascular partnering by industry sector since 2009
  • Figure 7: Cardiovascular partnering by stage of development since 2009
  • Figure 8: Cardiovascular partnering by technology type since 2009
  • Figure 9: Cardiovascular partnering by cardiovascular target since 2009
  • Figure 10: Cardiovascular deals with a headline value
  • Figure 11: Cardiovasular deal headline value distribution, US$million - discovery stage
  • Figure 12: Cardiovasular deal headline value distribution, US$million - preclinical stage
  • Figure 13: Cardiovasular deal headline value distribution, US$million - phase I stage
  • Figure 14: Cardiovasular deal headline value distribution, US$million - phase II stage
  • Figure 15: Cardiovasular deal headline value distribution, US$million - phase III stage
  • Figure 16: Cardiovasular deal headline value distribution, US$million - regulatory stage
  • Figure 17: Cardiovasular deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2009-2014
  • Figure 19 Cardiovasular deals with upfront payment values
  • Figure 20: Cardiovascular deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Cardiovascular deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Cardiovascular deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Cardiovascular deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Cardiovascular deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Cardiovascular deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Cardiovascular deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2009-2014
  • Figure 28: Cardiovascular deals with milestone payments
  • Figure 29: Cardiovascular deal milestone distribution, US$million - discovery stage
  • Figure 30: Cardiovascular deal milestone distribution, US$million - preclinical stage
  • Figure 31: Cardiovascular deal milestone distribution, US$million - phase I stage
  • Figure 32: Cardiovascular deal milestone distribution, US$million - phase II stage
  • Figure 33: Cardiovascular deal milestone distribution, US$million - phase III stage
  • Figure 34: Cardiovascular deal milestone distribution, US$million - regulatory stage
  • Figure 35: Cardiovascular deal milestone distribution, US$million - marketed stage
  • Figure 36: Cardiovascular deals with royalty rates, %
  • Figure 37: Cardiovascular deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Cardiovascular deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Cardiovascular deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Cardiovascular deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Cardiovascular deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Cardiovascular deal royalty rate distribution, US$million - regulatory stage
  • Figure 44: Summary median royalty rate by stage of development, 2009-2014
  • Figure 45: Top cardiovascular deals by value since 2009
  • Figure 46: Top cardiovascular deals signed by bigpharma value since 2009
  • Figure 47: Online partnering resources
  • Figure 48: Forthcoming partnering events
Show More
Pricing
Get Notified
Email me when related reports are published